However, the hormone, glucagon, continues to suppress hunger pangs in people with type 1 diabetes, researchers found.
The primary role of glucagon, secreted by the pancreas, is to signal the body to release stored glucose when blood sugar falls too low.
But growing evidence suggests the hormone may also play a role in controlling food intake and feelings of fullness, or satiation, through signaling the body to reduce levels of other appetite hormones like ghrelin.
"Further research is needed to determine why glucagon no longer suppresses appetite effectively in this population, even though they are otherwise healthy," Arafat said.
The prospective, double-blinded, placebo-controlled study investigated glucagon levels and appetite among 11 obese people, 13 people with type 1 diabetes and 13 lean people.
Participants received injections of either glucagon or a placebo. Researchers then measured participants' appetites using a satiety scale as well as levels of the appetite hormone ghrelin.
In comparison, participants who were lean or had type 1 diabetes reported feeling significantly more full after receiving glucagon. The response to the hormone was detectable in this population, even 24 hours after it was administered.
"The findings could influence efforts to develop new treatments for obesity and diabetes," Arafat said.
"Although therapeutic agents that influence glucagon and other hormones currently are considered a promising avenue for research, this study suggests a treatment involving glucagon may be ineffective in controlling meal size in people who are obese," Arafat added.